VELTASSA is the only K+ binder with a sodium-free exchange1,2
Sodium may cause issues for your patients who cannot tolerate an increase in sodium load.
Systolic and diastolic blood pressure during 52 weeks of treatment with VELTASSA3*
| Systolic and diastolic blood pressure during 52 weeks of treatment with VELTASSA3* | ||||
|---|---|---|---|---|
| Group | Baseline Mean (mmHg) | Week 4 Mean change from baseline (mmHg) | Week 8 Mean change from baseline (mmHg) | Week 52 Mean change from baseline (mmHg) |
| Mild HK (>5.0 to 5.5 mEq/L) | 153.5/83.6 | –11.2/–6.8 | –14.2/–7.3 | –15.7/–8.0 |
| Moderate–severe HK (>5.5 to <6.0 mEq/L) | 153.8/81.9 | –8.0/–5.8 | –7.9/–4.7 | –17.1/–9.2 |
Scroll to view*AMETHYST-DN 52-week study (N=304).
No edema warning
The prescribing information for VELTASSA does not include a warning about edema.
Calcium and phosphate levels of VELTASSA patients
Next